Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Express Scripts
Dow
Medtronic
Harvard Business School
McKinsey

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Gimeracil

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Gimeracil: Patents, clinical trial progress, indications

Gimeracil is an investigational drug.

There have been 59 clinical trials for Gimeracil. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Stomach Neoplasms, Pancreatic Neoplasms, and Carcinoma. The leading clinical trial sponsors are Fudan University, Taiho Oncology, Inc., and Quintiles, Inc.

There are one hundred and fourteen US patents protecting this investigational drug and nine hundred and thirty-six international patents.

Recent Clinical Trials for Gimeracil
TitleSponsorPhase
SOX-based CRT for Esophageal Cancer.Zhejiang Provincial People’s HospitalPhase 1/Phase 2
S-1 for 9 Months Versus 1 Year for Gastric Cancer Staged II(SMAC)Fudan UniversityPhase 2
Tegio Consolidation Therapy for NPC Patients With High Risk of MetastasisZhejiang Cancer HospitalPhase 2

See all Gimeracil clinical trials

Clinical Trial Summary for Gimeracil

Top disease conditions for Gimeracil
Top clinical trial sponsors for Gimeracil

See all Gimeracil clinical trials

US Patents for Gimeracil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gimeracil   Start Trial Metal-salen complex compound, local anesthetic and antineoplastic drug IHI Corporation (Tokyo, JP) Ishikawa; Yoshihiro (Tokyo, JP)   Start Trial
Gimeracil   Start Trial Multimodal silica-based nanoparticles   Start Trial
Gimeracil   Start Trial Device and method for drug evaluation and local treatment Kibur Medical, Inc. (Boston, MA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Medtronic
McKesson
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.